# Diffuse Large B-Cell Lymphoma (DLBCL)

## Diagnosis
- Patients must be ≥18 years of age
- Histologically confirmed DLBCL
- Demonstration of CD19 Positive expression on target tissue

## Treatment History & Prognosis
- Relapsed or refractory disease after ≥ 2 lines chemotherapy
- Either having failed stem cell transplant or being ineligible for / or not consenting to stem cell transplant
- Life expectancy ≥ 12 weeks without Chemotherapy
- Patient must be off PD-L1 inhibitor treatment for at least 6 weeks prior to expected CAR-T Cell infusion.

## Physical Assessment
- Measurable disease at time of referral: extranodal lesions (outside lymph node or nodal mass, but including liver and spleen) ≥ 10 mm in long AND short axis
- Karnofsky Performance Score (KPS) ≥ 70%

## Organ Function
Patients must have adequate organ function. The ranges below are a guide for your patient to qualify for CAR-T*.

### Renal function:
- Serum creatinine of ≤ 1.6 mg/dL
- Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m²

### Liver function:
- ALT or AST ≤ 3x upper limit of normal value for age
- Bilirubin ≤ 2x upper limit of normal value for age

### Pulmonary function:
- Pulse oxygenation > 91% on room air

### Cardiac function:
- Left ventricle ejection fraction (LVEF) ≥ 40% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)

### Bone marrow function
- Absolute neutrophil count (ANC) > 1.0 x 10⁹/L
- Absolute lymphocyte count (ALC) > 0.1 x 10⁹/L(100/mm³) NOTE: If ALC is below 0.1 x 10⁹/L, application can be considered; but for apheresis to proceed, ALC must be at least 0.1 x 10⁹/L
- Absolute number of CD3+ T cells >150/mm³
- Hemoglobin > 80 g/L (8.0g/dl)
- Platelets ≥ 50 x 10⁹/L 50, 000/mm³

## Exclusion Criteria
- Active CNS involvement
- Prior anti-CD19 therapy
- Pregnancy
- HIV, Hepatitis C, active/uncontrolled Hepatitis B